NIH VideoCast - COVID-19: Developing a Vaccine During a Pandemic

Skip Navigation

COVID-19: Developing a Vaccine During a Pandemic

Loading... Loading video...

1,215 Views

Air date:	Thursday, February 4, 2021, 12:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 1,215 (862 Live, 353 On-demand)
Category:	COVID-19
Runtime:	01:00:58
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	COVID-19 Scientific Interest Group Dr. Barouch is the William Bosworth Castle Professor of Medicine and Professor of Immunology at Harvard Medical School and director of the Center for Virology and Vaccine Research at the Beth Israel Deaconess Medical Center. His talk will outline the current state of the COVID-19 vaccine field and will describe the development of the Ad26.COV2.S vaccine — a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein. My laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. I have also recently demonstrated the therapeutic efficacy of potent monoclonal antibodies and the early seeding of the viral reservoir. My laboratory received three NIH U19 Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program grants in 2005, 2008, and 2012 to construct alternative serotype adenovirus vaccine vectors, to explore their immunogenicity and protective efficacy in rhesus monkeys, and to advance optimal vaccine candidates into clinical trials. Four phase 1 clinical trials with these vectors have been completed in the United States and sub-Saharan Africa. My laboratory also received an NIH U19 grant in 2011 to establish a consortium for AIDS vaccine research in nonhuman primates and four Gates Foundation consortium grants in 2011, 2012, 2013, and 2014 to develop replicating adenovirus vectors, nonhuman primate adenovirus vectors, novel Env protein immunogens, and therapeutic broadly neutralizing monoclonal antibodies in both preclinical studies and clinical trials. For more information go to https://oir.nih.gov/sigs/covid-19-scientific-interest-group

NLM Title:	COVID-19 : developing a vaccine during a pandemic / Dan Barouch ; COVID-19 Scientific Interest Group.
Author:	Barouch, Dan H. National Institutes of Health (U.S.). COVID-19 Scientific Interest Group,
Publisher:
Abstract:	(CIT): Dr. Barouch is the William Bosworth Castle Professor of Medicine and Professor of Immunology at Harvard Medical School and director of the Center for Virology and Vaccine Research at the Beth Israel Deaconess Medical Center. His talk will outline the current state of the COVID-19 vaccine field and will describe the development of the Ad26.COV2.S vaccine -- a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein.My laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine strategies. I have also recently demonstrated the therapeutic efficacy of potent monoclonal antibodies and the early seeding of the viral reservoir. My laboratory received three NIH U19 Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program grants in 2005, 2008, and 2012 to construct alternative serotype adenovirus vaccine vectors, to explore their immunogenicity and protective efficacy in rhesus monkeys, and to advance optimal vaccine candidates into clinical trials. Four phase 1 clinical trials with these vectors have been completed in the United States and sub-Saharan Africa. My laboratory also received an NIH U19 grant in 2011 to establish a consortium for AIDS vaccine research in nonhuman primates and four Gates Foundation consortium grants in 2011, 2012, 2013, and 2014 to develop replicating adenovirus vectors, nonhuman primate adenovirus vectors, novel Env protein immunogens, and therapeutic broadly neutralizing monoclonal antibodies in both preclinical studies and clinical trials. F
Subjects:	COVID-19 Vaccines--therapeutic use Clinical Trials as Topic Drug Development Pandemics--prevention & control Treatment Outcome
Publication Types:	Lecture Webcast

NLM Classification:	WC 506.6
NLM ID:	101776725
CIT Live ID:	41236
Permanent link:	https://videocast.nih.gov/watch=41236

Related Videos...